Table 2.
Dosimetric comparison and statistical analysis of PTV coverage
Item | PTV location | Median (range, min–max) | p value* | ||||
---|---|---|---|---|---|---|---|
IMRT | PSPT | SSPT | IMRT vs PSPT | IMRT vs SSPT | PSPT vs SSPT | ||
PTV CI | WV | 0.85 (0.72–0.88) | 0.70 (0.69–0.71) | 0.91 (0.89–0.92) | <0.05 | <0.05 | <0.05 |
PG | 0.92 (0.87–0.92) | 0.83 (0.62–0.87) | 0.94 (0.90–0.90) | <0.05 | <0.05 | <0.05 | |
SS | 0.89 (0.88–0.92) | 0.74 (0.72–0.83) | 0.92 (0.90–0.94) | <0.05 | <0.05 | <0.05 | |
BG | 0.88 (0.86–0.91) | 0.80 (0.74–0.82) | 0.94 (0.93–0.95) | <0.05 | <0.05 | <0.05 | |
PTV GI | WV | 3.30 (3.08–3.75) | 1.90 (1.85–2.04) | 2.12 (1.99–2.19) | <0.05 | <0.05 | <0.05 |
PG | 3.89 (3.47–4.62) | 2.90 (2.50–3.25) | 2.50 (2.36–3.34) | <0.05 | <0.05 | NS | |
SS | 3.82 (3.71–4.14) | 2.78 (2.64–3.27) | 2.59 (2.48–2.87) | <0.05 | <0.05 | NS | |
BG | 3.77 (3.46–4.23) | 2.35 (2.18–2.57) | 2.30 (2.23–2.60) | <0.05 | <0.05 | NS | |
PTV HI | WV | 0.97 (0.96–0.98) | 0.95 (0.94–0.95) | 0.98 (0.98–0.98) | <0.05 | <0.05 | <0.05 |
PG | 0.96 (0.95–0.97) | 0.97 (0.96–0.98) | 0.98 (0.97–0.98) | NS | <0.05 | NS | |
SS | 0.96 (0.95–0.97) | 0.97 (0.96–0.98) | 0.97 (0.95–0.98) | NS | NS | NS | |
BG | 0.97 (0.97–0.98) | 0.97 (0.97–0.98) | 0.97 (0.97–0.98) | NS | NS | <0.05 | |
PTV PQI | WV | 4.06 (3.82–4.73) | 2.89 (2.75–3.11) | 2.37 (2.23–2.46) | 0.043 | 0.043 | 0.043 |
PG | 4.39 (3.92–5.55) | 3.38 (3.12–5.47) | 2.70 (2.54–3.83) | 0.043 | 0.043 | 0.043 | |
SS | 4.46 (4.26–4.88) | 3.92 (3.62–4.05) | 2.95 (2.88–3.12) | 0.043 | 0.043 | 0.043 | |
BG | 4.45 (4.00–4.93) | 3.01 (2.81–3.59) | 2.49 (2.44–2.86) | 0.043 | 0.043 | 0.043 |
WV whole ventricle, PG pineal gland, SS suprasellar, BG basal ganglia, PTV planning target volume, CI conformity index, GI gradient index, HI homogeneity index, PQI plan quality index, IMRT intensity-modulated radiation therapy, PSPT passively scattered proton therapy, SSPT spot scanning proton therapy, NS not significant
* p -value by Wilcoxon signed rank test